NVCN
Neovasc Inc. [NVCN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVCN Stock Summary
In the News
NVCN Financial details
Company Rating
-
Market Cap
82.86M
Income
-44.64M
Revenue
3.81M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-1.84
Forward P/E
-
PEG
-0.28
P/S
21.78
P/B
-
P/C
-
P/FCF
-3.32
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-16.36
EPS next Y
-
EPS next Q
-
EPS this Y
52.53%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-62.02%
Revenue last 5Y
16.82%
Revenue Q/Q
57.36%
EPS Q/Q
63.23%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-
ROE
-225%
ROC
-
Gross Margin
80%
Oper. Margin
-887%
Profit Margin
-1173%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.585-30.07
52W High
+0.1%
52W Low
+650.75%
RSI
-
Rel Volume
-
Avg Volume
25.78K
Volume
1
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.0138
-
-
Volatility
0%, 0%
Prev Close
0%
Price
30.03
Change
0%
Company Profile
- Volume Average 25.78K
- Market Capitalization 82.86M
- Employee 49
- CEO Mr. Fredericus A. Colen
- Headquarters Richmond,BC,CA
- IPO Date 2001-05-23
-
Website
https://www.neovasc.com 
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
